Anxiety and Depression Comorbidity: What the Overlap Means for Research and Treatment

Anxiety and depression are classified as separate disorders, but they share the same patient far more often than chance would predict. This overlap is not a footnote. It shapes who gets into studies, what the studies measure, and whether results apply to the people who actually need treatment.

How common is the overlap?

In the National Comorbidity Survey Replication, a nationally representative US sample of over 9,000 adults, more than 60% of respondents with major depressive disorder met criteria for at least one anxiety disorder, and roughly half of those with an anxiety disorder met criteria for major depression at some point in their lives [1]. In primary care, a study of nearly a thousand patients found that 56% of those with an anxiety disorder also had depression, and the comorbid group reported significantly greater impairment and disability [7].

These are not borderline cases being double-counted. The overlap is large, consistent across studies and persistent over time. A meta-analysis of 66 longitudinal studies found that anxiety and depression predict each other bidirectionally: anxiety at one time point predicts later depression, and depression predicts later anxiety, with roughly similar effect sizes in each direction [6].

Structural models of the overlap

If two conditions co-occur this often, they may not be fully separate. The tripartite model, proposed by Clark and Watson in 1991, offered an influential framework: both anxiety and depression share a common factor of high negative affect (general distress, nervousness, irritability). What makes them distinct is that anxiety adds physiological hyperarousal (racing heart, shortness of breath), while depression adds anhedonia — the absence of positive affect [2].

This model is supported by factor-analytic studies, but it does not explain all of the overlap. Genetic research tells a complementary story. A meta-analysis of twin and family studies found that anxiety disorders are moderately heritable (30–40%) and that the genetic factors predisposing to anxiety overlap substantially with those predisposing to depression [5]. In twin studies, the genetic correlation between generalized anxiety disorder and major depression is so high — around 0.8 — that some researchers have argued they are genetically the same condition expressing differently.

The Hierarchical Taxonomy of Psychopathology (HiTOP) takes this further. Instead of treating anxiety and depression as discrete categories, it places them on a shared “internalizing” spectrum alongside other conditions characterized by negative emotion [4]. Under this framework, comorbidity is not surprising — it is what you would expect when you draw arbitrary category boundaries across a continuous dimension.

How comorbidity affects trial evidence

Most treatment trials focus on one diagnosis. A trial of CBT for social anxiety disorder, for example, typically requires participants to have social anxiety as their primary diagnosis and may exclude those with severe depression. This makes the sample cleaner and the results easier to interpret, but it also makes the sample unrepresentative.

People in real clinical settings usually have both. A treatment shown to work in carefully selected participants with pure social anxiety may perform differently when the person is also struggling with depression that saps their motivation to do exposure homework. Some trials have examined this:

• Several trials report that comorbid depression predicts worse outcomes in anxiety treatment, though the effect is inconsistent.
• CBT for anxiety disorders often improves depressive symptoms as well, even when depression is not directly targeted, which suggests shared mechanisms are being engaged.
• When comorbid depression is severe, therapists may need to address motivational and behavioral activation issues before anxiety-focused work can proceed.

The trouble is that comorbidity is often poorly reported. A trial may exclude participants above a depression severity threshold but not state what that threshold was, or may report anxiety outcomes without mentioning whether comorbid depression moderated the results.

Transdiagnostic treatments

If anxiety and depression share core processes, perhaps they can be treated together. The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders targets shared mechanisms — emotional avoidance, cognitive rigidity, distress intolerance — rather than disorder-specific symptoms.

In a randomized trial, the Unified Protocol was compared with established single-disorder protocols (CBT for specific anxiety disorders) in 223 adults with anxiety. The Unified Protocol produced equivalent outcomes, and it also improved depressive symptoms comparably [3]. The practical advantage is that a single treatment framework can be applied regardless of the specific diagnostic mix.

Whether transdiagnostic treatments are genuinely better than well-chosen disorder-specific treatments, or merely more efficient for training and delivery, is still debated. The evidence so far suggests “comparable” more than “superior.”

What this means for reading research

When you encounter a study of an anxiety treatment, consider the comorbidity question:

1. Who was included? Were participants required to have pure anxiety, or were comorbid conditions allowed?
2. Who was excluded? A common exclusion is “current major depressive episode” — which removes exactly the patients most likely to present in practice.
3. Were depression symptoms measured? If not, you don’t know whether the treatment helps or harms the condition most participants also have.
4. Was comorbidity examined as a moderator? The most informative trials test whether results differ for people with and without comorbid depression.

For more on how diagnostic boundaries affect what a study measures, see what does an anxiety study measure?.

What remains uncertain

Whether anxiety and depression are truly separate conditions or points on a shared spectrum is an active debate. Diagnostic manuals still separate them, and this separation shapes research funding, clinical training and treatment guidelines. The dimensional models are gaining influence but have not yet changed clinical practice in most settings. How best to treat the person with both — sequential disorder-specific treatment, simultaneous treatment, or transdiagnostic treatment — does not yet have a clear winner in the evidence.

When to look for more support. If you recognize both anxiety and depression in yourself and they are affecting your daily functioning, a GP can assess both and discuss treatment options. Many treatments help both conditions. If you are in crisis or having thoughts of self-harm, contact emergency services or call/text 988 (US) or 116 123 (UK and Ireland, Samaritans).